ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag patent genetics genomics

Different colored cartoon viruses entering holes in a cartoon of a human brain.
A Journey Into the Brain
Danielle Gerhard, PhD | Mar 22, 2024 | 10+ min read
With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.
Genome patents need purpose
Andrea Gawrylewski | Aug 4, 2008 | 2 min read
The British High Court's rejection linkurl:last week;http://www.the-scientist.com/blog/display/54909/ of a biotech company's patent on the genetic sequence coding for a therapeutically important protein may be a warning for other biotechs who hold patents on portions of the human genome. The court ruled last week that a patent held by Human Genome Sciences since the mid 1990s was invalid because at the time the company applied for the patent they hadn't demonstrated a practical use. The patent
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Biotech Faces Evolving Patent System
Douglas Steinberg | Mar 5, 2000 | 8 min read
Like medieval alchemists, modern biologists apply intricate, esoteric protocols to lowly matter, such as bacteria and rodents. Unlike alchemists, biologists successfully transmute these creatures into gold--disease-fighting pharmaceuticals and profits accruing from them. An indispensable ingredient in this dross-to-drug process is patent protection, which preserves monopoly and attracts investment. Unfortunately, the patent system isn't as ideal a catalyst as the chimerical philosopher's stone s
Watson Departure Vexes Genome Experts
Scott Veggeberg | May 24, 1992 | 4 min read
They fear that funding support for their vast gene-mapping project could erode now that the Nobelist is leaving While the head of the nation's premier health agency may not be losing sleep over the resignation of James Watson as head of the Human Genome Project (HGP), many genetic researchers are distressed to see him go. Genome scientists interviewed for this article say it will be difficult for the National Institutes of Health, via its search committee, to find someone with the same drive
Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
Patents On Some Science Findings Would Present Problems
Dorothy Nelkin | Nov 22, 1992 | 5 min read
Date: November 23, 1992 Editor's Note: Indications are that the National Institutes of Health's controversial gene-patenting initiative, now widely seen as moribund, is really as good as dead. At press time, a final decision on the matter was still in the hands of Secretary of Health and Human Services Louis Sullivan, but sources at HHS feel the initiative is on insecure legal footing and will be dropped. Before the proposal more or less gave up its ghost, however, it served to stimulate anim
Privatizing the Human Genome?
Paul Smaglik | Jun 7, 1998 | 10 min read
Principals behind joint-venture proposal and public effort seek to define relationships A private effort to sequence the human genome four years ahead of the Human Genome Project's 2005 goal could either compete directly with the federal project or meld seamlessly with it. Before any relationship between the two efforts becomes formalized, scientists and federal officials involved with the Human Genome Project must determine whether the private approach will work, who will own the data, how qu
Will Genomics Spoil Gene Ownership?
Douglas Steinberg | Sep 3, 2000 | 8 min read
Consider a scenario for the year 2002: Using commercially available software, bioprospector "Craig Collins" spends a day scavenging the Human Genome Project (HGP) database for the alternatively spliced genes prized by Wall Street. He enters the sequences of several candidate genes into a software package that prints out the likely functions of their protein products. One protein looks like it could be pharmaceutical paydirt, so he isolates the corresponding cDNA, inserts it into a vector, then
Gene Patenting Is On The Rise, But Scientists Are Unimpressed
Franklin Hoke | Apr 16, 1995 | 8 min read
Buoyed by enabling legislation and scientific advances, institutions are aggressively shopping their faculties' `blue-sky' investigations. In just the past year, patents on the genes implicated in obesity, breast cancer, and other disorders have generated headlines in newspapers across the United States. In several of these cases, scientists have turned their patented discoveries into lucrative commercial deals worth several times their funding from other sources--crucial money in light of pro

Run a Search

ADVERTISEMENT